This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Early Winners & Losers

Sprint (S) tumbled nearly 9% after the closing bell rang Monday on reams of bad news. The Reston, Va.-based company lost 306,000 postpaid subscribers in the fourth quarter, will slash about 5,000 jobs (more than 7% of its year-end headcount) and has forecast bleak full-year results.

The company will likely bring in revenue of $41 billion in 2006 -- more than $533 million below Wall Street projections, according to Thomson Financial. Fourth-quarter results should be better: At $12.6 billion to $12.9 billion, they handily beat the $10.47 billion consensus. Also, 2007 full-year revenue is pegged at $41 billion to $42 billion, which just about covers the mean Street estimate. Shares, however, were losing $1.71 to $17.93.

Thermage (THRM - Get Report) jumped on better-than-expected preliminary results. The Hayward, Calif., medical equipment maker said it probably brought in a top line between $14.6 million and $14.8 million in the fourth quarter, or about 58% more than last year. Analysts are seeking $14.3 million. Shares were adding 54 cents, or 7.2%, to $8.05.

Osiris Therapeutics (OSIR - Get Report) gained after the Food and Drug Administration granted the Baltimore-based biotech "fast track" status in order to finish developing its stem-cell treatment for a resistant form of Crohn's disease (inflammation of the digestive tract). The treatment, called Prochymal, was also approved for advanced-phase testing. Prior midphase testing on Prochymal yielded statistically significant results in Crohn's disease patients who didn't respond to standard therapies. Shares were rising $1.13, or 4.5%, to $26.20.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CAKE $54.59 0.00%
EMAG $20.67 0.00%
OSIR $16.97 0.00%
SCSC $37.41 0.00%
S $4.47 0.00%


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs